Training for VA clinicians to support Veterans with Long-COVID

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on improving care for Veterans suffering from Long-COVID through a two-part intervention. In Part 1, the study will refine and test a Concordant Care training program aimed at enhancing clinician engagement in validating patient experiences and creating personalized care plans. Part 2 will evaluate the effectiveness of this training by comparing clinician practices and patient outcomes between those receiving the training and those receiving standard education materials. The study aims to gather feedback from both Veterans and clinicians to optimize the training process.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Part 1 and Part 2, English-speaking VA primary care providers will be included.
* Part 1, Veterans who self-identify as having Long-COVID will be included.
* Part 2, Veterans who meet criteria for Long-COVID assessed with modified DePaul Symptom Questionnaire version 2 will be included;
* Part 2, Veterans must also have a scheduled appointment with one of the participating clinicians within one to six months of the clinician being consented.

Exclusion Criteria:

* Part 1 and Part 2, clinicians who have already taken Concordant Care training will be excluded.
* Part 1, Veterans will be excluded if they are not receiving care in the VA.
* Part 2, Veterans will be excluded if they were in the Intensive Care Unit (ICU) for COVID-19.

Where it's running

• East Orange Campus of the VA New Jersey Health Care System, East Orange, NJ
  East Orange, New Jersey, United States Recruiting

Study contacts

• Principal investigator: Lisa Marie McAndrew, PhD — East Orange Campus of the VA New Jersey Health Care System, East Orange, NJ
• Study coordinator: Lisa M McAndrew, PhD
• Email: Lisa.Mcandrew@va.gov
• Phone: (862) 400-3317

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Second cohort following patients entering a multidisciplinary care pathway for post-COVID syndromes (SyPoCo2)

  This project will test whether linking long COVID patients' symptoms with blood immune and molecular markers can find biomarkers and possible treatment targets.

  Recruiting at 2 sites Hospices Civils de Lyon · Pierre-Bénite and 1 other locations · NCT07356570

• Accelerated intermittent theta-burst stimulation for depression with post‑COVID‑19 condition

  This will test whether two different schedules of intermittent theta-burst stimulation (accelerated TMS) reduce depressive symptoms and inflammation in adults aged 18–65 who have depressive disorder plus post‑COVID‑19 condition.

  Recruiting Max-Planck-Institute of Psychiatry · Munich, Bavaria · NCT07197138

• 2-HOBA to reduce persistent immune activation in Long COVID with POTS

  This trial will test whether 2‑HOBA, a compound that scavenges harmful IsoLG-adducts, can reduce immune activation in adults with Long COVID who have POTS.

  Recruiting Phase 2 Vanderbilt University Medical Center · Nashville, Tennessee · NCT07189936

• Long COVID relief through learning mindfulness

  This study will try an 8-week online recorded mindfulness program to see if it reduces stress and Long COVID symptoms in adults who continue their usual care.

  Recruiting Columbia University · New York, New York · NCT07140094

• Investigating dysfunctional breathing in patients with post COVID-19 condition

  This study is trying to see how breathing problems affect people who are dealing with long-term symptoms after having COVID-19.

  Recruiting Karolinska Institutet · Stockholm, Solna and 1 other locations · NCT06776263

• Evaluating Apabetalone for Long-COVID in Diabetes Patients

  This study is testing if adding a new medication called Apabetalone to the diabetes drug dapagliflozin can help people with Type 2 Diabetes who are dealing with Long-COVID symptoms feel better.

  Recruiting Phase 2/3 Resverlogix Corp · Amman and 2 other locations · NCT06590324

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.